Third-generation tetracyclines, including tigecycline, eravacycline, and omadacycline, are advanced antibiotics with broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria. These drugs have been developed to overcome resistance mechanisms such as efflux pumps and ribosomal protection. Tigecycline, a glycylamido derivative of minocycline, is effective against tetracycline resistance mechanisms and has a long half-life, making it suitable for intravenous use. Eravacycline, a fluorocycline, has a higher affinity for ribosomal binding and is effective against multidrug-resistant pathogens. Omadacycline, an aminomethylcycline, has improved bioavailability and is effective against various bacteria, including those resistant to other antibiotics. These tetracyclines have shown potential beyond their antimicrobial properties, including immunomodulatory and anti-cancer effects. They are used in treating infections such as community-acquired bacterial pneumonia, acute bacterial skin and soft tissue infections, and multidrug-resistant Acinetobacter species. Tigecycline is effective against Mycobacterium abscessus and Clostridioides difficile, while eravacycline and omadacycline also show promise in treating these infections. Omadacycline has demonstrated efficacy against tuberculosis and Helicobacter pylori strains. Resistance mechanisms include efflux pumps, enzymatic inactivation, and modifications in the ribosomal target. These mechanisms can lead to reduced effectiveness of the drugs. Despite these challenges, third-generation tetracyclines remain important in treating severe infections, particularly those caused by drug-resistant bacteria. They are also being explored for their potential in combination therapies with other antibiotics, such as rifampicin, aminoglycosides, and polymyxin B, to enhance their effectiveness. Overall, third-generation tetracyclines offer significant therapeutic potential in the treatment of various infections, especially in hospital settings.Third-generation tetracyclines, including tigecycline, eravacycline, and omadacycline, are advanced antibiotics with broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria. These drugs have been developed to overcome resistance mechanisms such as efflux pumps and ribosomal protection. Tigecycline, a glycylamido derivative of minocycline, is effective against tetracycline resistance mechanisms and has a long half-life, making it suitable for intravenous use. Eravacycline, a fluorocycline, has a higher affinity for ribosomal binding and is effective against multidrug-resistant pathogens. Omadacycline, an aminomethylcycline, has improved bioavailability and is effective against various bacteria, including those resistant to other antibiotics. These tetracyclines have shown potential beyond their antimicrobial properties, including immunomodulatory and anti-cancer effects. They are used in treating infections such as community-acquired bacterial pneumonia, acute bacterial skin and soft tissue infections, and multidrug-resistant Acinetobacter species. Tigecycline is effective against Mycobacterium abscessus and Clostridioides difficile, while eravacycline and omadacycline also show promise in treating these infections. Omadacycline has demonstrated efficacy against tuberculosis and Helicobacter pylori strains. Resistance mechanisms include efflux pumps, enzymatic inactivation, and modifications in the ribosomal target. These mechanisms can lead to reduced effectiveness of the drugs. Despite these challenges, third-generation tetracyclines remain important in treating severe infections, particularly those caused by drug-resistant bacteria. They are also being explored for their potential in combination therapies with other antibiotics, such as rifampicin, aminoglycosides, and polymyxin B, to enhance their effectiveness. Overall, third-generation tetracyclines offer significant therapeutic potential in the treatment of various infections, especially in hospital settings.